Yesterday's migraine treatment breakthrough, though amidst a complex journey to find a cure, still promises a dramatic impact despite the absence of a 'magic bullet.'
Coordinating with Migraine and Headache Awareness Month (MHAM), this June, Pfizer has announced it is partnering with multi-award winning, singer and actress, Lady Gaga, who was diagnosed with migraine when she was 14.
Impel Pharmaceuticals’ Trudhesa treatment, paired with its Precision Olfactory Delivery system, reportedly shows promise to women suffering from the condition.
The company’s Precision Olfactory Delivery technology, currently combined with its Trudhesa migraine treatment, reportedly facilitates high absorption rates.
Biohaven’s drug for acute treatment of migraine, manufactured using Catalent’s Zydis technology for orally disintegrating tablets, receives approval from the US FDA.
US FDA gives marketing authorization to Lilly’s oral medication for the acute treatment of migraines in adult patients, adding to its Emgality approval almost exactly a year ago.
The acquisition of two migraine therapies from Dr Reddy’s has been completed by Upsher-Smith, adding different drug delivery treatment options to its migraine product portfolio.
Zosano completes site qualification batches for its subcutaneous investigational migraine treatment and readies itself for NDA submission by the end of year.
Endo Pharmaceuticals, which previously lost a bid to acquire a migraine treatment, has now acquired worldwide rights to Sumavel DosePro (sumatriptan injection) for subcutaneous use, which is a needle-free delivery system for Zogenix’s migraine treatment...
Avanir Pharmaceuticals has bought North American rights to OptiNose’s novel intranasal delivery system to treat acute migraines, which is expected to be filed for US FDA approval by early 2014.
New data from an early-stage trial of Vectura's inhaled migraine
candidate VR147 suggest that it could offer significant advantages
over currently-available treatments.
Zogenix says that proceeds from a planned $86m initial public
offering (IPO) will be used to fund development of its pipeline of
needle-free medicines for pain and central nervous system
indications.
It has the same name and the same active ingredient, but
GlaxoSmithKline claims to have significantly improved its migraine
treatment Imitrex (sumatriptan) with a new formulation that
dissolves rapidly in the stomach.
